Health Care [ 5/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 25 | -0.08 Increased by +68.00% | -0.11 Increased by +25.02% |
| Nov 7, 24 | -0.10 Increased by +69.70% | -0.13 Increased by +21.07% |
| Aug 13, 24 | -0.13 Increased by +58.06% | -0.16 Increased by +18.75% |
| May 14, 24 | -0.21 Increased by +55.32% | -0.16 Decreased by -31.25% |
| Mar 28, 24 | -0.25 Increased by +41.86% | 0.09 Decreased by -377.78% |
| Nov 9, 23 | -0.33 Increased by +2.94% | 0.03 Decreased by -1.20 K% |
| Aug 10, 23 | -0.31 Increased by +24.39% | -0.35 Increased by +11.43% |
| May 11, 23 | -0.47 Increased by +55.24% | -0.29 Decreased by -62.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -6.74 M Increased by +17.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.11 M Increased by +23.30% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.47 M Increased by +15.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.57 M Increased by +12.34% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Increased by +100.00% | -8.14 M Increased by +5.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.27 M Decreased by -36.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.84 M Decreased by -8.35% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -10.91 M Increased by +34.85% | Decreased by N/A% Decreased by N/A% |